Get the Stockscreener App
9.04
2.38%
0.21
Pre-market:
8.80
-0.24
-2.65%
Olema Pharmaceuticals Inc stock is traded at $9.04, with a volume of 1.49M.
It is up +2.38% in the last 24 hours and down -13.33% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$8.83
Open:
$8.79
24h Volume:
1.49M
Relative Volume:
1.20
Market Cap:
$790.98M
Revenue:
-
Net Income/Loss:
$-185.15M
P/E Ratio:
-4.4635
EPS:
-2.0253
Net Cash Flow:
$-148.72M
1W Performance:
-8.69%
1M Performance:
-13.33%
6M Performance:
-35.10%
1Y Performance:
+8.26%
1-Day Range:
$8.59
$9.27
1-Week Range:
$8.59
$10.13
52-Week Range:
$6.65
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
9.04 | 790.98M | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-19-26 | Resumed | Jefferies | Buy |
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.1%Time to Sell? - MarketBeat
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Olema Pharmaceuticals at H.C. Wainwright: pipeline bets on breast cancer By Investing.com - Investing.com Canada
Olema Pharmaceuticals (OLMA) Slips to $9.75 as Shares Sit Mid-Range Between Key LevelsBreak of Structure - dars.gov.et
Goldman Sachs Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA) - The Globe and Mail
OLMA Maintained by Stifel -- Price Target Lowered to $30 - GuruFocus
Stifel cuts Olema Pharmaceuticals price target on trial concerns By Investing.com - Investing.com Nigeria
Why is Olema Pharmaceuticals stock sliding today? By Investing.com - Investing.com Canada
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results - finance.yahoo.com
Olema Pharmaceuticals (OLMA) Shares Drop 15% After AstraZeneca B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 4.4%Here's Why - MarketBeat
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $59 - Moomoo
Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Squarepoint Ops LLC - MarketBeat
OLMA: Phase III breast cancer trials for palazestrant target over $15B in global market opportunities - TradingView
Olema Oncology at citigroup summit: palazestrant data, delays - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 3.5%Should You Buy? - MarketBeat
Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1'27 (NASDAQ:OLMA) - Seeking Alpha
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne - Quiver Quantitative
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036 - Stock Titan
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Olema Pharmaceuticals Inc. (OLMA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals Inc. (OLMA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of America Corp DE Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. OLMA Stock Forecast & Price Target - Yahoo! Finance Canada
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Olema Oncology appoints Jason O’Byrne as CFO - The Pharma Letter
OLMA Maintained by JP Morgan -- Price Target Lowered to $46.00 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals, Inc. Announces Appointment of Jason O?Byrne to Chief Financial Officer, Effective August 11, 2026 - marketscreener.com
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46 - moomoo.com
Olema Pharmaceuticals Names Jason O'Byrne as New CFO with Comprehensive Compensation Package - Kalkine Media
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
HC Wainwright Brokers Decrease Earnings Estimates for OLMA - MarketBeat
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - The Manila Times
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech - Stock Titan
Olema Pharmaceuticals Names Jason O'Byrne CFO - finance.yahoo.com
Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harmon Cyrus - Moomoo
Olema stock falls 12.9% as Q2 loss widens to $63.2M on R&D spend - scanx.trade
OLMA Maintains Rating by Citigroup -- Price Target Lowered to $5 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup - MarketBeat
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):